TY - JOUR
T1 - Adult Moyamoya Disease and Syndrome
T2 - Current Perspectives and Future Directions: A Scientific Statement from the American Heart Association/American Stroke Association
AU - Gonzalez, Nestor R.
AU - Amin-Hanjani, Sepideh
AU - Bang, Oh Young
AU - Coffey, Christopher
AU - Du, Rose
AU - Fierstra, Jorn
AU - Fraser, Justin F.
AU - Kuroda, Satoshi
AU - Tietjen, Gretchen E.
AU - Yaghi, Shadi
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Adult moyamoya disease and syndrome are rare disorders with significant morbidity and mortality. A writing group of experts was selected to conduct a literature search, summarize the current knowledge on the topic, and provide a road map for future investigation. The document presents an update in the definitions of moyamoya disease and syndrome, modern methods for diagnosis, and updated information on pathophysiology, epidemiology, and both medical and surgical treatment. Despite recent advancements, there are still many unresolved questions about moyamoya disease and syndrome, including lack of unified diagnostic criteria, reliable biomarkers, better understanding of the underlying pathophysiology, and stronger evidence for treatment guidelines. To advance progress in this area, it is crucial to acknowledge the limitations and weaknesses of current studies and explore new approaches, which are outlined in this scientific statement for future research strategies.
AB - Adult moyamoya disease and syndrome are rare disorders with significant morbidity and mortality. A writing group of experts was selected to conduct a literature search, summarize the current knowledge on the topic, and provide a road map for future investigation. The document presents an update in the definitions of moyamoya disease and syndrome, modern methods for diagnosis, and updated information on pathophysiology, epidemiology, and both medical and surgical treatment. Despite recent advancements, there are still many unresolved questions about moyamoya disease and syndrome, including lack of unified diagnostic criteria, reliable biomarkers, better understanding of the underlying pathophysiology, and stronger evidence for treatment guidelines. To advance progress in this area, it is crucial to acknowledge the limitations and weaknesses of current studies and explore new approaches, which are outlined in this scientific statement for future research strategies.
KW - AHA Scientific Statements
KW - cerebral revascularization
KW - diagnosis
KW - guidelines as topic
KW - hemorrhagic stroke
KW - moyamoya disease
UR - http://www.scopus.com/inward/record.url?scp=85172425468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172425468&partnerID=8YFLogxK
U2 - 10.1161/STR.0000000000000443
DO - 10.1161/STR.0000000000000443
M3 - Review article
C2 - 37609846
AN - SCOPUS:85172425468
SN - 0039-2499
VL - 54
SP - E465-E479
JO - Stroke
JF - Stroke
IS - 10
ER -